Atossa Therapeutics Inc (ATOS)
1.48
+0.06
(+4.23%)
USD |
NASDAQ |
Apr 23, 16:00
1.49
+0.01
(+0.68%)
After-Hours: 20:00
Atossa Therapeutics Cash from Financing (TTM): -1.475M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -1.475M |
September 30, 2023 | -1.475M |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.001M |
June 30, 2022 | 0.68M |
March 31, 2022 | 10.88M |
December 31, 2021 | 113.30M |
September 30, 2021 | 147.18M |
June 30, 2021 | 150.83M |
March 31, 2021 | 140.98M |
December 31, 2020 | 38.55M |
September 30, 2020 | 4.672M |
June 30, 2020 | 0.3476M |
March 31, 2020 | 0.00 |
December 31, 2019 | 11.34M |
September 30, 2019 | 11.34M |
June 30, 2019 | 11.34M |
March 31, 2019 | 23.63M |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | 4.696M |
September 30, 2016 | 4.703M |
June 30, 2016 | 2.088M |
March 31, 2016 | 7.331M |
December 31, 2015 | 9.457M |
September 30, 2015 | 9.351M |
June 30, 2015 | 9.555M |
March 31, 2015 | 4.394M |
December 31, 2014 | 13.06M |
September 30, 2014 | 14.54M |
June 30, 2014 | 22.69M |
March 31, 2014 | 25.89M |
December 31, 2013 | 13.94M |
September 30, 2013 | 15.92M |
June 30, 2013 | 8.103M |
March 31, 2013 | 4.858M |
December 31, 2012 | 3.849M |
September 30, 2012 | 0.4705M |
June 30, 2012 | -0.0111M |
March 31, 2012 | 5.524M |
December 31, 2011 | 5.530M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.475M
Minimum
Sep 2023
150.83M
Maximum
Jun 2021
33.60M
Average
4.672M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
AngioDynamics Inc | -59.25M |
Biolase Inc | 17.43M |
Outset Medical Inc | 43.65M |
Perspective Therapeutics Inc | 0.785M |
Electromed Inc | -0.128M |